Benefits of Hemodialysis Plus Hemoperfusion: A Clinical Study

Inclusion Criteria: Age 18-80 years, regardless of gender Stable maintenance hemodialysis for ≥ 3 months with relatively fixed dialysis pattern Hemodialysis treatment 3 times per week, total treatment duration ≥ 10 hours per week, vascular access unlimited Blood β2-MG > 30 mg/L and/or 300 pg/ml < immunoreactive parathyroid hormone (iPTH) < 800 pg/ml and/or CRP ≥ 16.2 pg/ml Kt/V ≥ 1.2 eight weeks prior to enrollment Signed informed consent form Exclusion Criteria: Known allergic reaction, contraindication or intolerance to the material of the dialyzer or perfusion apparatus Test indicators meeting one or more of the following: white blood cell <4 x 10^9/L, platelet count <60 x 10^9/L, serum albumin <30 g/L Blood flow <200 ml/min Regular hemoperfusion treatment for more than 3 months and at least once every 2 weeks Active bleeding or chronic gastrointestinal bleeding, or other severe bleeding tendencies or coagulation disorders History of unstable angina pectoris, myocardial infarction, severe arrhythmia, pericarditis, myocarditis, cardiac surgery or peripheral vascular surgery in the last 8 weeks Cerebral hemorrhage in the last 12 weeks Severe heart failure (New York Heart Association class IV) Acute infection, acute or critical illnesses such as severe cardiac, pulmonary, hepatic or neurological disease and malignancy Pregnancy or breastfeeding Participation in a clinical trial or ongoing clinical trial within 3 months Expected survival of less than 1 year Not considered suitable for participation in this trial by the investigator